BMC Infectious Diseases: Advancing Infectious Disease Research in Support of SDG 3
Published in Microbiology, Biomedical Research, and General & Internal Medicine
Infectious diseases continue to shift and evolve, reshaping the health needs of communities around the world. At BMC Infectious Diseases, we’ve seen a growing urgency for research that not only deepens scientific understanding but also directly supports global health efforts, including the shared ambition of SDG 3: Good Health and Well‑Being.
As part of the upcoming SDG 3 newsletter on Infectious Diseases, we want to spotlight four of our newest Collections. Each Collection focuses on a critical area where evidence is needed, innovation is emerging, and global collaboration has the potential to move the needle on public health.
Personalized Medicine in Infectious Diseases
The promise of personalized medicine is no longer abstract in infectious disease research, it’s here, and it’s moving quickly. Where treatments once relied on broad, standardized approaches, precision diagnostics and genomics are opening the door to more tailored, effective interventions.
Guest edited by Dr Emma Sweeney and Dr Zhenwei Yu, this Collection on Personalized Medicine in Infectious Diseases brings together research exploring biomarker‑driven diagnostics, individualized antimicrobial strategies, and model‑informed dosing, all essential tools in addressing treatment resistance and improving patient outcomes.
Research in this space directly supports SDG 3 by strengthening our ability to deliver safer, more precise care.
Innovations in HIV Testing, Surveillance, and Treatment
Despite remarkable scientific progress, HIV remains one of the world’s most persistent health challenges. Guest edited by Dr Tiffany Phillips and Dr Bin Su, the Innovations in HIV Testing, Surveillance, and Treatment Collection focuses on what’s new and what’s next: rapid and point‑of‑care diagnostics, improved surveillance methods, long‑acting therapeutics, and strategies that make “test and treat” more accessible and effective.
As countries work toward the SDG 3.3 target of ending communicable disease epidemics, the research shared in our Collection supports more responsive, equitable, and accessible HIV care for communities everywhere.
Malaria in the 21st Century: Diagnostics, Resistance, and Control Strategies
Malaria control is at a pivotal moment. Advances in molecular diagnostics and vaccine development offer new promise, while resistance continues to pose familiar obstacles.
Guest edited by Dr Rajesh Chandramohanadas, Dr Loick P. Kojom Foko, Professor Ayodhia Pitaloka Pasaribu, and Dr Duoquan Wang, the Malaria in the 21st Century: Diagnostics, Resistance, and Control Strategies Collection invites research that deepens our understanding of evolving parasite biology, strengthens detection and surveillance, and supports robust control strategies.
These insights are essential for informing more resilient public health strategies and supporting the SDG 3.3 efforts towards malaria control and elimination.
Tropical Vector‑Borne Infectious Diseases
Vector‑borne infections, such as dengue, Zika, and chikungunya, continue to expand in geographical reach and intensity. With climate change and urbanization reshaping transmission patterns, understanding these diseases has never been more important.
Guest edited by Dr Maíra Aguiar, Dr Shengzhang Dong, Dr Marta Giovanetti, and Dr Wasin Matsee, this Collection on Tropical Vector‑Borne Infectious Diseases presents research on surveillance approaches, ecological drivers, diagnostic improvements, and integrated vector management strategies.
Strengthening evidence in this area supports communities most affected by vector‑borne outbreaks and aligns closely with SDG 3’s focus on epidemic preparedness.
Looking Ahead
Taken together, these four Collections illustrate the amount of work needed to understand and respond to infectious diseases in a rapidly changing world. Each opens space for interdisciplinary collaboration, innovative thinking, and research that can generate real‑world impact.
We look forward to seeing how the research community continues to push the field forward and to sharing the work that emerges through these Collections.
Do you want to join the conversation and submit your research? Explore these topics and more on the BMC Infectious Diseases Collections and Calls for Papers page.
This blog was written as part of April’s upcoming SDG 3 Newsletter on Infectious Diseases. To read the full newsletter as soon as it lands, follow Alice Coe and Virginia Mercer on Research Communities.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Personalized medicine in infectious diseases
BMC Infectious Diseases invites submissions for a Collection on Personalized medicine in infectious diseases.
The field of personalized medicine is rapidly advancing, particularly among infectious diseases, where the traditional ‘one-size-fits-all’ treatment approaches are increasingly inadequate. As our understanding of the genetic, environmental, and lifestyle factors influencing disease susceptibility and treatment response grows, this Collection aims to explore innovative strategies and technologies that can enhance the application of personalized medicine in combating infections.
Recent advancements in genomics, pharmacogenomics, and bioinformatics are transforming the application of personalized approaches for infectious diseases. These developments have enabled the identification of specific biomarkers that inform individualized treatment strategies, improving patient outcomes and minimizing adverse effects. In parallel, advances in molecular diagnostics and tailored antimicrobial therapies offer new opportunities to address the escalating challenge of antimicrobial resistance.
Improved understanding of host-pathogen interactions and the genetic determinants of infections may support the development of targeted antiviral and antimicrobial strategies that enhance their effectiveness, while limiting the emergence of resistance. Research in this area may also enable personalized antimicrobial dosing and optimized treatment guidelines that balance individual patient benefits with broader public health considerations.
This Collection welcomes original research articles on topics including but not limited to:
- Tailored antimicrobial therapy in infectious diseases
- Patient-specific interventions to improve clinical outcomes
- Personalized strategies to address antimicrobial resistance
- Precision medicine approaches in antiviral therapy
- Novel methodologies for disease modelling and therapeutic targeting
- Precision diagnostics, including biomarker validation and metagenomic sequencing
- Model-informed personalized dosing in infectious diseases
- Therapeutic drug monitoring in anti-infective therapy
This Collection supports and amplifies research related to SDG 3 (Good Health and Well-being).
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Dec 16, 2026
Tuberculosis and co-infections: diagnostics, management, and treatment
BMC Infectious Diseases invites submissions for a Collection on Tuberculosis and co-infections: diagnostics, management, and treatment.
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, particularly in regions with high prevalence rates and co-infections. The interplay between TB and various co-infections (including bacterial, viral, parasitic and fungal), complicates diagnosis and treatment strategies. Advances in molecular diagnostics and imaging techniques have improved our understanding of how these co-morbidities affect TB pathogenesis and treatment outcomes. However, the challenge of managing drug-resistant TB adds an additional layer of complexity, necessitating a comprehensive approach that integrates the latest research findings with clinical practice.
Research into TB of all stages and its co-infections is crucial for addressing the rising incidence of drug resistance and improving patient outcomes. Recent studies have identified critical biomarkers for early detection and prognosis, highlighting the role of rapid diagnostic tools in the clinical setting. Additionally, understanding the mechanisms of co-infections has led to tailored treatment regimens that maximize efficacy while minimizing adverse effects. Nonetheless, gaps remain in our knowledge of optimal management strategies for these complex cases, emphasizing the need for ongoing research in this field.
Future research endeavors should focus on the development of more effective diagnostic techniques and treatment protocols that consider the multifaceted interactions between TB and its co-infections. Innovations in personalized medicine may lead to targeted therapies that address specific pathogen interactions, ultimately enhancing patient recovery rates. Moreover, collaborative efforts between public health entities and research organizations could pave the way for comprehensive TB surveillance systems, fostering the identification of emerging trends in co-infection patterns.
This Collection welcomes original research articles on topics including but not limited to:
- Diagnostic innovations for Tuberculosis and co-infections
- Management strategies for drug-resistant Tuberculosis
- Interaction between Tuberculosis and HIV
- Tuberculosis and diabetes comorbidity
- Tuberculosis in the context of viral hepatitis and COVID-19
This Collection supports and amplifies research related to SDG 3 (Good Health and Well-being).
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jan 27, 2027
